We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Citations

Citations to this article as recorded by  

• Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
  Yassine Lalami, Camillo Garcia, Patrick Flamen, Lieveke Ameye, Marianne Paesmans, Ahmad Awada
  Head & Neck.2016; 38(3): 347.     CrossRef
• A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis
  Ch'angbum Rim, Jung-Ae Lee, Soojung Gong, Dong Wook Kang, Heebum Yang, Hyun Young Han, Nae Yu Kim
  Journal of Gastric Cancer.2016; 16(2): 115.     CrossRef
• PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER
  Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall, Federica Morandi
  Veterinary Radiology & Ultrasound.2012; 53(3): 348.     CrossRef
• Phase II study of sunitinib as second-line treatment for advanced gastric cancer
  Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero
  Investigational New Drugs.2011; 29(6): 1449.     CrossRef